{'fraction_non_alphanumeric': 0.025193798449612403, 'fraction_numerical': 0.003875968992248062, 'mean_word_length': 5.08235294117647, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ERJ August Podcast: Fevipiprant in allergic asthma not controlled by low-dose inhaled corticosteroids

As part of the August issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc Humbert discusses the publication of the results of a trial of fevipiprant, an oral prostaglandin in DP2 receptor (CRTh2) antagonist, in allergic asthma that is not controlled by low-dose inhaled corticosteroids with Prof. Eric D. Bateman from the University of Cape Town, South Africa.